Compass Pathways Launches First U.S. TRD Awareness Day with Mental Health Advocates
Event summary
- Compass Pathways (Nasdaq: CMPS) initiated the first U.S. Treatment-Resistant Depression (TRD) Awareness Day on October 14, 2026, in collaboration with leading mental health organizations.
- TRD affects approximately 4 million people in the U.S., with fewer than 5% currently on TRD-indicated treatment.
- A new survey found 95% of TRD patients describe themselves as struggling or barely getting by, with 66% of caregivers reporting significant mental health tolls.
- Compass Pathways is developing COMP360 psilocybin, a proprietary synthetic psilocybin treatment for TRD, with Breakthrough Therapy designation from the FDA.
The big picture
Compass Pathways' TRD Awareness Day underscores the growing recognition of treatment-resistant depression as a distinct and underserved condition within mental health care. The collaboration with major advocacy groups highlights the strategic importance of patient-centric approaches in advancing biotech solutions for high-unmet-need indications. The initiative comes as Compass Pathways continues to lead the world's largest classic psychedelic clinical program, positioning itself at the forefront of a potential paradigm shift in psychiatric treatment.
What we're watching
- Regulatory Progress
- The pace at which COMP360 psilocybin advances through clinical trials and secures regulatory approvals for TRD and PTSD.
- Market Adoption
- Whether Compass Pathways can sustain momentum in raising awareness and securing partnerships to drive adoption of TRD treatments.
- Patient Outcomes
- How early recognition and treatment of TRD through awareness initiatives impact patient outcomes and caregiver burden.
Related topics
